Treatment schedule
| Drug . | Dose . | Route . | Days . |
|---|---|---|---|
| Induction | |||
| ATO | 0.15 mg/kg | IV (2 h) | 1-* |
| IDA | 12 mg/m2 | IV (30 min) | † |
| MTX, AraC, PSL | 15 mg, 40 mg, 10 mg | IT | ‡ |
| Consolidation #1 | |||
| ATO | 0.15 mg/kg | IV (2 h) | 1-25 |
| MTX, AraC, PSL | 15 mg, 40 mg, 10 mg | IT | ‡ |
| Consolidation #2 | |||
| ATO | 0.15 mg/kg | IV (2 h) | 1-25 |
| MTX, AraC, PSL | 15 mg, 40 mg, 10 mg | IT | ‡ |
| Consolidation #3 | |||
| AraC | 2 g/m2, every 12 h | IV (3 h) | 1-4 |
| PBSCH | § | ||
| Autologous HCT | |||
| Busulfan | 1 mg/kg, every 6 h | po | −6, −5, −4 |
| Melphalan | 70 mg/m2 | IV (bolus) | −3, −2 |
| PBSCT | 0 |
| Drug . | Dose . | Route . | Days . |
|---|---|---|---|
| Induction | |||
| ATO | 0.15 mg/kg | IV (2 h) | 1-* |
| IDA | 12 mg/m2 | IV (30 min) | † |
| MTX, AraC, PSL | 15 mg, 40 mg, 10 mg | IT | ‡ |
| Consolidation #1 | |||
| ATO | 0.15 mg/kg | IV (2 h) | 1-25 |
| MTX, AraC, PSL | 15 mg, 40 mg, 10 mg | IT | ‡ |
| Consolidation #2 | |||
| ATO | 0.15 mg/kg | IV (2 h) | 1-25 |
| MTX, AraC, PSL | 15 mg, 40 mg, 10 mg | IT | ‡ |
| Consolidation #3 | |||
| AraC | 2 g/m2, every 12 h | IV (3 h) | 1-4 |
| PBSCH | § | ||
| Autologous HCT | |||
| Busulfan | 1 mg/kg, every 6 h | po | −6, −5, −4 |
| Melphalan | 70 mg/m2 | IV (bolus) | −3, −2 |
| PBSCT | 0 |
IT, intrathecally; IV, intravenously; MTX, methotrexate; PBSCH, peripheral blood stem cell harvest; PBSCT, peripheral blood stem cell transplantation; po, by mouth; PSL, prednisolone.
For induction, ATO was administered until complete remission or for 60 d, whichever was shorter.
IDA was added for 2 d if the WBC count exceeded 20.0 × 109/L before or during the induction therapy, if the combined total count of myeloblasts and promyelocytes in the peripheral blood exceeded 5.0 × 109/L before or during the induction therapy, or if an extramedullary myeloid tumor was detected before the induction therapy.
Intrathecal injection was given when the platelet count recovered after the end of the courses. PSL could be replaced with 4 mg of dexamethasone.
PBSCH was performed when the WBC count had recovered.